Intrathecal Pumps MarketSize and Trends

Intrathecal pumps market scenario is shaping favorably for sustained growth over the following decade

Major changes in the pump therapy for chronic diseases are likely to be observed during the forecast period 2017-2025. Intrathecal pumps are widely used to relive chronic pain in cancer. According to a survey conducted by the International Agency for Research on Cancer (IARC) in 2012, new cases of cancer were estimated to be 14.1 million and mortality rate was approximately 8.2 million. According to a survey conducted by the World Health Organization (WHO) and International Pain Community in 2011, the prevalence of chronic pain in cancer was evaluated around 25% for newly identified patients and greater than 75% for patients with progressive disease. The demand for advanced intrathecal pumps will extensively upsurge in future with increasing cases of chronic illnesses.

Intrathecal pump device is expected to evolve with several companies working on new technologies that would improve the functioning of programmable pump, internal mechanism, and safety. In 2014, Food and Drug Administration (FDA) approved the ‘Prometra’ intrathecal pump launched by Flowonix Medical Inc. ‘Prometra’ have various features, such as accurate drug delivery system, dual-gated valve drug distribution, and improved device durability. The other area of interest in the intrathecal space is the development of new drugs that could be delivered to treat specific alignments. For instance, FDA approved number of medications, such as Ziconotide (2004), Spinraza (2016), and probuphine (2016), which have been proven to be safe for intrathecal administration.

Market- Trends